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Portal hypertension induces a splanchnic and systemic low-grade inﬂammatory response that could induce the expression of
three phenotypes, named ischemia-reperfusion, leukocytic, and angiogenic phenotypes.During the splanchnic expression of these
phenotypes,interstitialedema,increased lymphﬂow,andlymphangiogenesis areproducedinthegastrointestinaltract.Associated
liver disease increases intestinal bacterial translocation, splanchnic lymph ﬂow, and induces ascites and hepatorenal syndrome.
Extrahepatic cholestasis in the rat allows to study the worsening of the portal hypertensive syndrome when associated with
chronic liver disease. The splanchnic interstitium, the mesenteric lymphatics, and the peritoneal mesothelium seem to create an
inﬂammatory pathway that could have a key pathophysiological relevance in the production of the portal hypertension syndrome
complications. The hypothetical comparison between the ascitic and the amniotic ﬂuids allows for translational investigation.
From a phylogenetic point of view, the ancestral mechanisms for amniotic ﬂuid production were essential for animal survival
out of the aquatic environment. However, their hypothetical appearance in the cirrhotic patient is considered pathological since
ultimately they lead to ascites development. But, the adult human being would take advantage of the potential beneﬁcial eﬀects of
this “amniotic-like ﬂuid” to manage the interstitial ﬂuids without adverse eﬀects when chronic liver disease aggravates.
1.Introduction
It has been proposed that low-grade inﬂammation related
to portal hypertension (PH) switches to high-grade inﬂam-
mation with the development of severe and life-threatening
complications when associated with chronic liver disease [1].
It is accepted that the underlying central theme in low-
grade portal hypertensive inﬂammation is the disturbance
in splanchnic and systemic hemodynamics [1, 2]. This
splanchnic and systemic hemodynamic response would be
aggravatedduringtheprogressionofthechronicliverdisease
[1, 2]. Thus, a critical state is produced in which the appear-
ance of noxious factors during the progressive evolution
of chronic liver disease would favor the development of a
high-grade splanchnic and systemic inﬂammatory response
[1, 3, 4].
In the current paper, we have considered that portal
hypertensive syndrome evolves in three stages of increasing
severity during which a body hydrosaline decompensation of
splanchnic origin is developed. This loss of hydrosaline body
homeostasis is fundamentally produced by PH, although it is
aggravated if liver disease is associated. From a histological
and anatomical point of view, we have hypothesized that,
ﬁrstly, the splanchnic interstitial space would be impaired,
after that the mesenteric lymphatic system would be dis-
turbed, and ﬁnally, the mesothelial peritoneal cavity would
be involved. In the following ﬁrst section of the paper,
we describe the evolution of PH when there are not2 International Journal of Inﬂammation
complications, particularly without associated liver disease.
In this case, the portal hypertensive syndrome induces
hyperdynamic splanchnic and systemic circulation, mesen-
teric venous vasculopathy, bacterial translocation to the
mesenteric lymph nodes, and liver steatosis with metabolic
syndrome. In the second and third sections, we explain
how the evolution of PH is when mild or moderate liver
insuﬃciency is associated.
2.TheRoleofMastCellsinthePathophysiology
of the Portal HypertensiveSyndrome
PH induces a splanchnic and systemic low-degree inﬂam-
matory response that could be developed through the
expression of three successive and overlapping phenotypes:
ischemia-reperfusion phenotype, leukocytic phenotype, and
angiogenic phenotype (Table 1). In turn, it has been already
proposed that these phenotypes could represent the expres-
sion of trophic functional systems with increasing metabolic
complexity [1, 5]. This hypothetical approach to the mech-
anisms that govern the systemic inﬂammatory response
could be based on the increasing metabolic ability of the
body over the successive phases of its evolution towards a
splanchnic and systemic remodeling. Therefore, in the portal
hypertensive patient, it could be considered that the body
adapts the support (the trophic system) to the metabolic
needs characteristic of each inﬂammatory phenotype. In
turn, the metabolic ability of each inﬂammatory phenotype
would be determined by the mechanism used for cellular
energy production [1, 2, 5]. Mast cells strategically located
close to blood vessels could be among the ﬁrst to respond to
the mechanical stimuli that initiate splanchnic inﬂammation
in PH [2]. If so, the early hemodynamic alterations would
favor an abnormal movement of ﬂuids into the interstitial
space which would subsequently induce the development of
asplanchniclymphatichyperdynamiccirculation.Moreover,
mediators released by mast cell could participate in this
lymphatic hyperdynamic circulation. When appropriately
activated mast cells have the ability to produce vasoactive
amines, enzymes, that is, proteases, cytokines, chemokines,
and growth factors through degranulation [1, 2]. This plas-
ticity of the mast cells can also show diverse responsiveness
during the splanchnic inﬂammatory response evolution, and
genetic and environmental factors can position them within
a broad spectrum of functional responsiveness. If so, mast
cells could successively participate in the expression of the
three trophic functional systems which have been previously
proposed as components of the inﬂammatory response [2].
Hyperdynamic circulation stands out among the
splanchnic and systemic alterations related to PH [6, 7].
It has been suggested that the splanchnic and systemic
vasodilatation is the initial step leading to the hyperdynamic
syndrome or progressive vasodilatory syndrome [6, 8].
Multiple organ failure in portal hypertensive chronic liver
disease is in large part attributable to this syndrome [7, 8].
Furthermore, hyperdynamic circulation could favor the
initiation and maintenance of an inﬂammatory response.
First, the pathological increase of the portal pressure
Table 1: Splanchnic inﬂammatory phenotypes in the portal hyper-
tensive syndrome.
(1) Ischemia-reperfusion phenotype
(i) Hyperdynamic blood circulation
(ii) Oxidative and nitrosative stress
(iii) Interstitial edema
(iv) Hyperdynamic lymphatic circulation
(2) Leukocytic phenotype
(i) Lymphatic immune dysfunction
(ii) Cell and bacterial interstitial translocation and activation
(iii) Interstitial enzymatic stress
(iv) Mesenteric adenitis
(v) Acute phase response
(3) Angiogenic phenotype
(i) Stromal remodeling
(a) Angiogenesis
(b) Lymphangiogenesis
(c) Fibrosis
(ii) Parenchymal remodeling
(a) Villous/crypt ratio decrease
(b) Goblet cell hyperplasia
(c) Hepatocytic steatosis
that occurs in the hyperdynamic splanchnic circulation
could favor a disturbed splanchnic venous ﬂow with shear
stress mediated by nonlaminar ﬂow [6]. The disturbed or
nonlaminar ﬂow produced by low shear stress has profound
eﬀects on the biology of the vascular wall, particularly the
vascular endothelium, and could stimulate inﬂammation
[9]. Second, both the increase in blood ﬂow speed and the
opening of arteriovenous shunts that induce the splanchnic
hyperdynamic circulation would reduce the oxygen tissue
availability. This fact would produce tissue hypoxia and
therefore the chronicity of the inﬂammatory response [2].
The ischemia-reperfusion phenotype secondary to the
hyperdynamic syndrome could present oxidative and
nitrosative stress with edema, which favors nutrition by
diﬀusion through the inﬂamed tissues and organs. This
hypothetical trophic mechanism has a low-energy require-
ment that does not require oxygen (ischemia-hypoxia),
and to a certain degree oxygen cannot be adequately
processed resulting in the production of reactive oxygen and
nitrogen species (ROS/RNS) (reperfusion-reoxygenation).
It is likely that the magnitude of tissues’s and organ
hypoxia is not uniformly distributed, which, in turn, would
determine the heterogeneity of the inﬂammatory response.
The venous hyperpressure associated with hypoxia could be
an important trigger of the splanchnic mast cell activation.
Degranulation of mast cells could result in the release of
potent vasodilator and exudative mediators such as his-
tamine, leukotrienes, cytokines, chemokines, and proteases
[2]. During the expression of this phenotype, while the
progression of the interstitial edema increases in the space
between the epithelial cells and the capillaries, the lymphatic
circulation is simultaneously activated (circulatory switch).International Journal of Inﬂammation 3
Thus, the injured tissue would adopt an ischemic phenotype
(hypoxia) [1, 2].
Theexpressionoftheleukocytic phenotype bythetissues
and organs which have suﬀered ischemia-reperfusion is
coupled with interstitial inﬁltration by inﬂammatory cells,
including mast cells, and sometimes by bacteria. Symbiosis
of the inﬂammatory cells and bacteria for extracellular
digestion by enzyme release (fermentation) and by intracel-
lular digestion (phagocytosis) could result in a hypothetical
trophic capacity. Improper use of oxygen persists in this
immune phase together with the presence of additional
enzymatic stress. Compensation of the acute-phase response
includes the production of positive acute-phase proteins
that bind proteolytic enzymes and inhibitors of leukocyte
and lysosomal proteolytic enzymes. Likewise, the natural
inhibitors of matrix metalloproteinases (TIMPs) could pro-
mote antienzymatic stress [1, 2].
PH induces bacterial translocation which is deﬁned as
the migration of viable microorganisms from the intestinal
lumen to the mesenteric lymph nodes and other extrain-
testinal organs and sites [10]. Bacterial overgrowth caused
by delayed intestinal transit and mucosal hypoperfusion and
oxidative damage, which increases intestinal permeability
and induces the transmural passage of bacteria, has been
considered among the crucial factors involved in bacterial
translocation that exists in PH [11, 12].
Furthermore, once activated by proinﬂammatory medi-
ators, mast cells migrate to mesenteric lymph nodes through
mesenteric lymphatic vessels and thus induce lymph node
hypertrophy [13]. The mesenteric lymph nodes are key
structures involved in the gut-associated lymphoid tissue
(GALT) [14]. GALT has an important function in the
maintenance of the intestinal mucosal integrity as well as in
thecontrolofmucosalinﬂammation.Inparticular,increased
inﬁltration by mast cells in the small bowel and mesenteric
lymph nodes in experimental PH suggests their involvement
in the development of portal hypertensive enteropathy and
therefore in bacterial translocation, through the release of
their multiple inﬂammatory mediators [10, 13]( Figure 1).
The activation of the mast cells in the mesenteric lymph
nodes in experimental PH would not only collaborate in the
production of mesenteric adenitis, but also would constitute
asourceofmediatorsfortheinﬂammatoryresponsebetween
thegastrointestinaltractandsystemicbloodcirculation[15].
GALT constitutes the largest lymphoid organ of the body,
and its activation in portal hypertensive enteropathy results
in the release of several inﬂammatory mediators. These
mediators would be transported by the intestinal lymph
vessels to the pulmonary circulation—inducing an inﬂam-
matory phenotype—and later to the systemic circulation.
The mesenteric lymph node circulation predominates, with
respect to portal circulation, for transporting inﬂammatory
mediators released in the intestinal wall in diﬀerent con-
ditions related to intestinal ischemia such as hemorrhagic
shock or severe burns [16]. In this way, in other conditions
that also produce intestinal ischemia, like PH, the mesenteric
lymph represents a splanchnic vehicle for proinﬂammatory
cytokines causing systemic eﬀects as well [5].
MLN
Lymph ﬂow
GII
HI
Figure 1: Splanchnic lymphatic ﬂow resulting from the gastroin-
testinal interstitium (GII) and the hepatic interstitium (HI) is
drained through the mesenteric lymph node (MLN) in physiologi-
cal situations.
It could be considered that remodeling by angiogenesis
characterizes the third phenotype of the portal hypertensive
inﬂammatory response (Table 1). Angiogenesis is deﬁned
as the growth of new vessels from preexisting ones [17].
Although the ﬁnal objective of endothelial growth is to
form new vessels for oxygen, substrates, and blood cells,
other functions could also be carried out before the new
vessels are formed. Particularly, it has been suggested that
in the early phases of the inﬂammatory response, the new
endothelial cells formed could have antioxidative, as well as
antienzymatic stress properties. In case of ongoing oxidative
and enzymatic stress, angiogenesis also plays a role in the
tissue and organ remodeling [1, 18]. Since in PH the basic
structuralalteration found in the gastrointestinal tract is vas-
cularandconsistsofincreasedsizeandnumberofthevessels,
the very appropriate name of “hypertensive portal intestinal
vasculopathy” has been proposed [19]. However, in addition
to vascular alterations, histological evidence of nonspeciﬁc
inﬂammation has been described in the gastroenteropathy
associated with PH [19]. Therefore, angiogenesis plays a
key role in development of portal hypertension (PHT) and
represents a potential therapeutic target [20].
Chronic inﬂammatory inﬁltration found in the small
bowel predominantly consists of mononuclear cells, and it
is accompanied by atrophy, a decreased villous/crypt ratio,
edema of the lamina propria, ﬁbromuscular proliferation,
and thickened muscularis mucosa [21, 22]. Since most of the
aforementioned characteristics can be explained on the basis
of increased levels of mast cell mediators [23], these cells4 International Journal of Inﬂammation
could be involved in the pathogenesis of portal hypertensive
chronic enteropathy [15]. Furthermore, in experimental
portal hypertensive enteropathy, the increased degree of
inﬁltration coexists with a higher vessel number in these
intestinal layers. Indeed, cell number shows a positive and
statistically signiﬁcant correlation with the vascular diameter
and total microvascular surface [24]. Splanchnic hyperemia,
increased splanchnic vascularization, and the development
of portal-systemic collateral circulation in experimental PH,
all are partly vascular endothelial growth factor (VEGF-)
dependent angiogenic processes [25, 26].
Long-term experimental PH shows persistent splanchnic
alterations related to portal hyperpressure with the changes
in the metabolism of lipids and carbohydrates that could
be involved in the development of liver steatosis as well
as in some of the manifestations described in the clinical
metabolic syndrome [27–29]. Thus, in experimental chronic
prehepatic PH, we have demonstrated the progressive fatty,
triglyceride,andcholesterolinﬁltrationofthelivercombined
with megamitochondria formation [28–30]. The mecha-
nisms by which PH could induce liver steatosis are not
fully understood. Nevertheless, the mechanisms that have
been proposed in order to explain the pathophysiology also
correspond with those expressed as result of a low-grade
chronic inﬂammatory state [2, 31]. If so, mast cells would
also be involved in the production of hypercholesterolaemia
and liver abnormalities. Particularly, the mast cell activation
syndrome should be considered a possible cause of hyper-
cholesterolaemia and of hepatic abnormalities of unknown
reason [32].
There is an intimate relationship between the immune
andmetabolicresponsesystemsthathavemanyevolutionary
underpinnings. Therefore, it is possible to imagine a situ-
ation in which common or overlapping pathways regulate
bothmetabolicandimmunefunctionsthroughcommonkey
regulatory molecules and signaling systems [33]. Moreover,
it is interesting to note that both adipose tissue and the
liver have an architectural organization in which metabolic
cells (adipocytes or hepatocytes) are in close proximity to
immune cells (Kupﬀer cells or macrophages), and both have
immediate access to a vast network of blood vessels [33].
Moreover, an important role of adaptive immunity has been
demonstrated in NASH, a condition found in the majority
of the patients who suﬀer from metabolic syndrome. In
these patients, adipose tissue could activate T cells which in
turnpromotetherecruitmentandactivationofmacrophages
in this tissue [34]. Since obesity fat-laden hepatocytes and
adipocytes share common features, it is also possible that
they may also share this immunologic T cell-mediated
pathogenic mechanism. That is why it has been suggested
that “obesity” neoantigens are involved in the production of
a chronic low-grade inﬂammation of the adipose tissue and
NASH in the development of metabolic syndrome [35].
Improper intestinal lymphatic function may also be
present and be propagated by the chronic low-grade intesti-
nal inﬂammation that PH presents. Intestinal lymphatic
transportfailurelikelyresultsinlymphaticimmunedysfunc-
tion,leadingtoincreasedinﬂammationandincreasedrelease
of inﬂammatory mediators, which could further impede the
Table 2: Characteristics of progressive portal hypertensive syn-
drome.
(i) Increased:
(a) Hyperdynamic blood circulation
(b) Hypoxia
(c) Sodium and water retention
(d) Lymph formation
(e) Hyperdynamic lymphatic circulation
(ii) Lymph leakage into peritoneal cavity
(iii) Ascites
(iv) Refractory ascites
(v) Bacterascites
(vi) Spontaneous bacterial peritonitis
(vii) Secondary bacterial peritonitis
(viii) Hepatorenal syndrome
(ix) Sepsis
(x) Hypotension and hypothermia
(xi) Severe sepsis
(xii) Septic shock
ability of lymphatics to function [36]. Lymphatic circula-
tion, both intestinal and extraintestinal, is an important
transporter of lipids and plays a role in metabolic function.
Dysfunctional lymphatics result in lymph stasis and leakage
which stimulates adipogenesis. Furthermore, failures in
lymphatic transport can result in marked lipid accumulation
throughout the body thus contributing to adipose tissue
hyperplasia [36, 37]. The expansion of the perilymphatic
adipose deposits also appears to occur with localized chronic
inﬂammation and is considered metabolically essential for
proper immune response and as a source of energy for
immune activation and proliferation [38, 39].
3.The Roleof Disturbed
SplanchnicLymph Drainageinthe
PortalHypertensiveSyndrome
Liver disease could be the most frequent factor for worsening
portal hypertensive syndrome and therefore the splanchnic
lymphatic function. Particularly, chronic liver disease and
cirrhosis aggravate this syndrome exceedingly and favor
lymphatic dysfunction [40]( Table 2). Therefore, it can be
hypothesized that when PH is associated with mild or
moderate liver disease, it would aggravate the hyperdy-
namic lymphatic splanchnic circulation, thus promoting
the dilation of the lymphatic vascular system and probably
a pathological lymphangiogenesis. Also, in this lymphatic
condition, the mediators released by the splanchnic mast
cells could participate.
Hepatic dysfunction related to ﬁbrosis or cirrhosis would
aggravate the grade of systemic inﬂammation characteristic
of the chronic portal hypertensive syndrome. Hepatic dys-
function produces splanchnic and systemic hyperdynamic
circulation which in turn favors lymphatic hyperdynamicInternational Journal of Inﬂammation 5
circulation. Increased lymph ﬂow is known to occur in
diﬀuse abnormalities of liver architecture such as ﬁbrosis
and cirrhosis [41, 42]. The size and number of lymphatics
are increased due to the excessive hepatic lymph production
which is caused by disturbance of the microcirculation typi-
cal of PH [42]. Expansion of lymphatics is also a prominent
feature of gastrointestinal inﬂammation. The dysregulation
of lymphatics in turn, exacerbates, gastrointestinal disease
[43]. During cirrhotic PH, dilation of esophageal and gastric
lymph vessels may be related to the absorption of excess
interstitial ﬂuid [44]. However, the main features of liver
decompensation in cirrhosis are ascites [45] hepatorenal
syndrome [40, 46], and hepatic encephalopathy [40].
Ascites and hepatorenal syndrome are the major chal-
lenging complications of cirrhosis and PH that signiﬁcantly
aﬀectthecourseofthedisease[47].Hepatorenalsyndromeis
aseriouscomplicationofend-stagedisease,occurringmainly
in patients with advanced cirrhosis and ascites who have
markedcirculatorydysfunction[46].Althoughascitescanbe
observed in multiple diseases [48], it is most frequent due
to cirrhosis with PH. The three major factors involved in
the pathogenesis of ascites are PH, arterial vasodilation, and
neurohormonalactivation,allofthemleadingtosodiumand
waterretention[47].Arteriolarvasodilationcausesunderﬁll-
ing of systemic arterial vascular space, with a decrease in the
eﬀective arterial blood volume. Consequently, baroreceptor-
mediatedactivationofrenin-angiotensin-aldosteronesystem
(RAAS), sympathetic and parasympathetic nervous systems,
and the release of antidiuretic hormone all aim at restoring
normal circulatory function [47, 49–51]. On the other
hand, splanchnic vasodilation increases splanchnic lymph
production exceeding the lymph transportation system
capacityandleadstolymphleakageintotheperitonealcavity
[52]. Persistent renal sodium and water retention, alongside
increased splanchnic vascular permeability in addition to
lymph leakage into peritoneal cavity, plays the major role in
asustainedascitesformation[50,52].Overtime,thestasisof
lymph ﬂow in lymphatic channels of the intestine could lead
to lymphangiectasia with an accompanying loss of proteins
and lymphocytes [53]. In the past, it was considered that
its treatment depended on a reduction of lymph formation
indirectly, that is, dietary restriction of salt and water and
diureticdrugs,ordirectly,thatis,portosystemicshunt,portal
decompression, or alternatively, an acceleration of an already
rapid lymph return (peritoneovenous shunt) to match the
high rate of lymph production. Conversely, factors that
favor lymph formation (i.e., mineralocorticoids, exogenous
salt) or inhibit lymph return (i.e., impaired lymphatic con-
tractility) or central nervous hypertension, intensify lymph
imbalance and worsen ascites [54]( Figure 2).
Other mechanisms proposed to be involved in ascites
formation are based on hepatorenal reﬂex, secondary to a
rapid increase in sinusoidal hepatic pressure [52, 55]a n d
the splenorenal reﬂex-mediated reduction in renal vascular
conductance, which exacerbates sodium and water retention
in the kidneys. This may eventually contribute to renal
dysfunction, and consequently ascites formation [56]. The
development of ascites is a major complication of cirrhosis
that induces an impaired quality of life and decreased
MLN
Inﬂammatory
lymphatic ﬂow
GII
HI
Figure 2: Chronic low-grade splanchnic inﬂammation in the
portal hypertensive syndrome increases mesenteric lymphatic ﬂow.
GII: Gastrointestinal interstitium; HI: Hepatic interstitium; MLN:
Mesenteric lymph nodes.
survival. The most diﬃcult patients to treat are those with
refractory ascites, which are characterized by a lack of
response to diuretic treatment [57].
Spontaneous bacterial peritonitis (SBP) is a frequent
and severe complication of decompensated cirrhosis [58].
Bacterial translocation is the key mechanism in its pathogen-
esis, and the common causative microorganisms are gram-
negative bacteria such as Escherichia coli and Klebsiella
pneumoniae. Other less frequent causative microorganisms
include pneumococci and streptococci [59]. SBP is often
clinically unapparent and requires a high index of suspicion
and almost always occurs in large-volume ascites in patients
with liver cirrhosis. Abdominal pain can be continuous and
is diﬀerent from tense ascites. Ascitic polymorphonuclear
leukocyte cell count is essential for diagnosis and man-
agement [58, 59]. However, the presence of fragments of
bacterial DNA can be identiﬁed by a polymerase chain
reaction (PCR-) based method and automated nucleotide
sequencinginpatientswithculture-negative,nonneutrocytic
ascites, indicating the existence of bacterial DNA (bactDNA)
translocation [60]. The presence of bacterial DNA in blood
and ascitic ﬂuid in a signiﬁcant number of patients with
decompensated cirrhosis without bacterial infections may
have an important role not only as a marker of bacterial
translocation, but also as a short-term prognostic factor
[60]. Paralytic ileus, hypotension, and hypothermia are
seen in advanced illness, possibly resulting in renal failure6 International Journal of Inﬂammation
(about one third of patients) or in death [50, 59]. Secondary
bacterial peritonitis is an infrequent complication in cir-
rhotic patients and presents a signiﬁcant more severe local
inﬂammatory response than in patients with SBP [60, 61].
On the contrary, bacterascites is the term used to describe
the colonization of ascitic ﬂuid by bacteria in the absence of
alocalinﬂammatoryreaction,whichsuggeststheconcurrent
failure of defensive mechanisms [59].
Thestandardviewofinﬂammationasareactiontoinjury
or infection might need to be expanded to account for the
inﬂammatory processes induced by other types of adverse
conditions [62]. Therefore, the splanchnic and systemic
impairments that are produced during the evolution of
the syndrome associated with PH could be considered
of an inﬂammatory nature. If so, and similar to other
types of inﬂammatory response, it would begin in the
interstitial space [18]( Table 3). The early inﬂammatory
response related to oxidative and nitrosative splanchnic
damage, lipid peroxidation, and hypometabolism, could be
associated with abnormal ion transport [1, 2]. There is
increasing evidence that those conditions characterized by
an intense inﬂammatory response have alterations in cellular
membrane potential, with depolarization and abnormal ion
transport [63]. Inﬂammatory mediators, which inﬂuence
ion transport, are interleukins, tumor necrosis factor alpha
(TNF-α), gamma-interferon(γ-IFN),bradykinin, and trans-
forming growth factor (TGFs) [63, 64]. They trigger the
release of speciﬁc messengers, like prostaglandins, nitric
oxide, and histamine, which alter the function of the ion
transport system through speciﬁc receptors, intracellular
second messengers, and protein kinases [63].
Thestandardviewofinﬂammationasareactiontoinjury
or infection might need to be expanded to account for the
inﬂammatory processes induced by other types of adverse
conditions [62]. Therefore, the splanchnic and systemic
impairments that are produced during the evolution of
the syndrome associated with PH could be considered
of an inﬂammatory nature. If so, and similar to other
types of inﬂammatory response, it would begin in the
interstitial space [18]( Table 3). The early inﬂammatory
response related to oxidative and nitrosative splanchnic
damage, lipid peroxidation and hypometabolism, could be
associated with abnormal ion transport [1, 2]. There is
increasing evidence that those conditions characterized by
an intense inﬂammatory response have alterations in cellular
membrane potential, with depolarization and abnormal ion
transport [63]. Inﬂammatory mediators, which inﬂuence
ion transport, are interleukins, tumor necrosis factor alpha
(TNF-α), gamma-interferon (γ-IFN), bradykinin and trans-
forming growth factor (TGFs) [63, 64]. They trigger the
release of speciﬁc messengers, like prostaglandins, nitric
oxide and histamine, which alter the function of the ion
transport system through speciﬁc receptors, intracellular
second messengers and protein kinases [63].
In addition, disturbances of ion transport are produced
in intra- and extracellular edema. It has been stated that
small ﬂuctuations in cell hydration or cell volume act as a
potent signal for cellular metabolism and gene expression.
Speciﬁcally, cell swelling triggers an anabolic signal [65].
Table 3: The continuum inﬂammatory splanchnic pathway of
Portal Hypertension.
(i) Interstitium
(a) Oxidative and nitrosative damage
(b) Abnormal ion transport
(c) Degradation of extracellular matrix
(d) Edematous inﬁltration
(e) Immune cells activation
(ii) Mesenteric lymphatics
(a) Increased ﬂuid ﬂow
(b) Increased transport of immune cells
(c) Toxins and bacteria translocation
(d) Lymphangiogenesis
(iii) Peritoneal mesothelium
(a) Oxidative and nitrosative stress
(b) Abnormal ion transport
(c) Immune activation
(d) Enzymatic stress
(e) Lymph leakage
(f) Ascites
Oxidative and nitrosative tissue damage could also increase
lipid peroxidation with increased membrane permeability,
increased degradation of extracellular matrix, and edema
[66]. The accumulation of glycosaminoglycan fragments
has been proposed as an important mechanism for edema
formation due to its hydrophilic properties [67].
Glycosaminoglycansarelongunbranchedpolysaccharide
chains that tend to adopt highly extended random coil
conformations and occupy a huge volume for their mass.
They attract and entrap water and ions, thereby forming
hydrated gels, while permitting the ﬂow of cellular nutri-
ents [67]. Under inﬂammatory conditions, hyaluronan, a
nonsulphated glycosaminoglycan, is more polydisperse with
preponderance to lowermolecular forms. Hyaluronan favors
edematous inﬁltration of the tissues as well as the interstitial
ﬂuid ﬂow and the tissue lymph pressure gradient [68].
Likewise, while the progression of interstitial edema reduces
the blood capillary function, it simultaneously enhances
lymphatic circulation (circulatory switch).
Furthermore, splanchnic interstitial ﬂow could be rele-
vant for lymphangiogenesis [69]. The interstitial ﬂuid ﬂow
associated with edema, even though it can be extremely
slow, can have important eﬀects on tissue morphogene-
sis and function, cell migration and diﬀerentiation and
matrix remodeling, among other processes [70]. Abnormally
increased interstitial ﬂow rates can occur during low-grade
inﬂammation and can also trigger ﬁbroblasts to diﬀerentiate
or remodel the extracellular matrix, thus contributing to the
development of tissue ﬁbrosis [70–74]. Interstitial ﬂow may
signiﬁcantly alter the distribution of metalloproteinases and
lymphaticgrowthfactorsinducinglymphaticendothelialcell
migration and capillary morphogenesis [69, 72]. Moreover,
upon splanchnic activation, mast cells, major eﬀecter cells
in host defense responses and immunity, release not onlyInternational Journal of Inﬂammation 7
vasoactive substances, histamine, and serotonin, but also
proteolytic enzymes favoring interstitial edema and remod-
eling [2]. Therefore, the substances which are released by the
stress systems in the blood during PH, that is, aldosterone,
renin, and catecholamines, will accumulate selectively in the
splanchnicinterstitialspacebecauseofanincreasedendothe-
lial permeability [1]. Mast cells and lymphatic vessels are
two important players in the development of the splanchnic
inﬂammatory process. Thus, it has been shown that in
vitro mast cells’ degranulation impairs lymphatic contractile
activity, probably through activation of H1 receptors by
histamine. It has been suggested that this action could
interfere with the expected ability of lymphatic vessels to
reduce edema during inﬂammation [75].
Unidirectional ﬂuid transport into the initial lymphatics
from the splanchnic interstitial space could be facilitated
by the primary and secondary valve systems and then by
the contractile lymphatics [76, 77]. Increasing evidence
suggests that lymphatic vessels might actively participate
in the inﬂammatory process. Lymph ﬂow is unidirectional
fromthelymphaticcapillariestolargercollectinglymphatics.
The forces that move the lymph along the collecting vessels
include smooth muscle contraction. Also, the collecting
lymphatic vessels are covered by smooth muscle cells and
have intraluminal valves for preventing the backﬂow of
lymph. This set of valves allows ﬂuid to enter the lymphatic
vessels, but not to escape. Oscillations in lymphatic pressure
produced by periodic expansion and compression of the
initial lymphatics cause the opening and closing of the
primary valves, and consequently lymph formation [77].
During inﬂammation, the elevation of lymphatic endothe-
lial permeability in an outward direction has two major
eﬀects. First, ﬂuid is being cleared from the tissue less
eﬃciently. With the increased permeability of the blood
vessels already producing more ﬂuid in the tissue than
normal,thedecreasedtransportbythelymphaticscausesthis
edema to increase even more. Second, the leaking lymphatics
allow inﬂammatory mediators to remain longer in the tissue
therefore increasing the inﬂammatory intestinal response
[77].
Mesenteric lymph transports cells (lymphocytes), lipids
(chylomicrons), proteins (plasma proteins, immunoglobu-
lins), enzymes (alkaline phosphatase, amylase), hormones
(insulin) and electrolytes (chloride and bicarbonate) to
the systemic circulation [76]. The biological role of the
mesenteric lymph in the pathogenesis of splanchnic and
systemic inﬂammation is not fully clariﬁed up to date.
However, there is now evidence showing that mesenteric
lymph plays a key role in the pathogenesis of multiple
organ dysfunction in trauma/hemorrhagic shock, burns,
reperfusion injury, and surgical stress [16, 76, 78–80]. The
hemodynamicalterationsthatPHimposesonthesplanchnic
circulation [6, 8] allow for considering that changes in the
mesenteric lymph ﬂow and composition are also produced.
If so, the mesenteric lymph could play an etiopathogenic role
in the multiple organ dysfunction developed in the portal
hypertensive syndrome. Particularly, bacteria and toxins,
like bacterial lipopolysaccharide (LPS) and inﬂammatory
mediators with high aﬃnity for chylomicrons, that is,
lipids, could use the mesenteric lymph vessels to bypass the
liver and induce a systemic response [81]. Worsening of
the splanchnic portal hypertensive inﬂammatory response
induced by hepatic dysfunction could increase the degree of
oxidative/nitrosative and enzymatic stress in the interstitial
space, favoring intestinal edema with mesenteric lymph
ﬂow and composition alterations. Lymphangiogenesis, the
formation of new lymphatic vessels, occurs in several patho-
logical conditions associated with chronic inﬂammation
[82, 83], including portal hypertensive enteropathy [44]
and liver cirrhosis [41, 42]. Inﬂammatory cells, through
the secretion of stimulatory factors such as VEGF-C and
TNF-α, can stimulate lymphatic endothelial cells [84–
86]. Lymphangiogenesis generally accompanies angiogenesis
[87], the basic structural alteration of the hypertensive
portal gastroenteropathy [19, 20]. However, pathological
lymphangiogenesis may occur in absence of blood vessels
[86, 88]. The biological role of lymphangiogenesis in
the pathogenesis of chronic inﬂammation needs further
clariﬁcation. Inﬂammation triggers lymphangiogenesis [89–
91] and may be beneﬁcial for the resolution of chronic
inﬂammation since lymphatic vessels remove inﬂammatory
cells and mediators from the inﬂammation sites [90, 92].
Lymphovenous communications located both in lymphatic
vessels and mesenteric lymph nodes [76] could also have
a pathophysiological signiﬁcance in the setting of chronic
intestinal inﬂammation that needs to be explored.
One highly specialized form of tissue remodeling in
chronic inﬂammation is lymphoid neogenesis, the develop-
ment of new lymphoid tissue in inﬂammatory sites [93, 94].
It has been proposed that during chronic inﬂammation,
lymphangiogenesis and lymphoid neogenesis would be syn-
ergistic processes that mutually amplify each other [94].
4.The Role of Mesothelial Cellsin
the Pathophysiology of the Portal
Hypertensive Syndrome
Hepatic dysfunction related to ﬁbrosis or cirrhosis would
aggravate the grade of systemic inﬂammation characteristic
of PH and as a result would increase the incidence of
complications [1, 2]. Consequently, the vascular dysfunc-
tion or hyperdynamic systemic and splanchnic circulation,
with increased mesenteric blood ﬂow and portal pressure,
would get worse, and interstitial hepatointestinal lymph ﬂow
would be favored. Splanchnic ischemia-reperfusion injury
secondary to the acute vascular dysfunction could result in
higher RAAS activity and excessive interstitial edema [47, 54,
95, 96]. The liver has been assumed to be the likely source of
ascites in patients with liver disease [41]. Nevertheless, the
cirrhotic liver is not the sole or even the major source of
ascites in most patients [47, 54]. Weeping of ﬂuid in great
excess from the peritoneal lining and serosal surfaces of the
bowel is often striking in PH as are dilated lymphatics on the
surfaceofthesmallintestine,inthemesenteryandwithinthe
retroperitonealspace[54].Therefore,itisacceptedthatwhen
lymphatic drainage mechanisms are overwhelmed, excess
lymph is collected in the peritoneal cavity, thus causing8 International Journal of Inﬂammation
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Figure 3: Acute-on-chronic splanchnic inﬂammation. Worsening
of the portal hypertensive syndrome is associated with ascites. The
ascitic ﬂuid increases the lymphatic mesenteric ﬂow as well as the
lymphatic capillary stasis in the interstitium, which in turn would
worsenthesplanchnicinﬂammatoryresponse.GII:Gastrointestinal
interstitium; HI: Hepatic interstitium; MLN: Mesenteric lymph
nodes; P: peritoneum.
ascites [50, 97, 98]( Figure 3). In summary, when PH is
associated with severe liver disease, a higher decompensation
of the splanchnic lymphatic system is induced since the
lymphatic vessels’ dilation plus the lymphangiogenesis do
nothaveenoughabilityfordrainingtheexcessivelymph.The
ﬁnal consequence is the spilling of the remaining lymph into
the peritoneal cavity with ascites which indeed in some cases
does not have an eﬃcient treatment.
Nevertheless, peritoneal mesothelial cells would not
be considered as a passive barrier for the lymph leakage
of splanchnic origin in ascites formation. In the normal
peritoneal cavity, mesothelial cells play an important role
as a source of intraperitoneal phospholipids. Demonstration
of the hydrophobic nature and surface tension-reducing
properties of this peritoneal secretion led to its comparison
with pulmonary surfactant [99]. In addition, the overlapped
peritoneal mesothelial cells have a surface covered with a
great number of microvillus and a cytoplasm ﬁlled with a
greater number of ribosomes, mitochondria, rough endo-
plasm reticulum, and Golgi apparatus [100]. Particularly,
the numerous pinocytic vesicles in the membrane and the
cytoplasm indicate active endo- exo- and transcytosis in the
process of secretion and reabsorption of peritoneal ﬂuid
[100]. These characteristics of the peritoneal mesothelial
(a) (b)
Figure 4: Liver and spleen in a sham-operated rat (a) and in a
microsurgical extrahepatic cholestatic rat (b).
cells suggest their active participation in the inﬂammatory
response, as a developer in the intestinal wall in portal
hypertensive syndrome, and therefore in ascites formation.
Peritoneal mesothelial cells could participate in the
splanchnic inﬂammatory response in experimental mod-
els of decompensated portal hypertensive syndromes, the
same occurs in the extrahepatic cholestatic rat. Obstructive
cholestasis is characterized by jaundice, discolored urine,
pale stools, and pruritus [101]. The serious repercussions of
cholestasis on the liver and on the systemic level have led to
the creation of many experimental models so as to better
understand its pathogenesis, prophylaxis, and treatment
[102, 103]. Obstructive cholestasis causes cirrhotic chronic
hepatic insuﬃciency and PH. Several surgical techniques
for developing obstructive cholestasis have been described,
especially in the rat. These techniques could be divided into
two groups, macrosurgical and microsurgical. Macrosurgical
techniques are based on the section of the common bile
duct between ligatures. These macrosurgical techniques of
obstructive extrahepatic cholestasis are called “bile duct
ligation” (BDL) and cause the development of infected hilar
biliary pseudocysts by dilation of the bile duct proximal end.
As a result, an important number of the animals die during
the ﬁrst 2 weeks of the postoperative period because of sepsis
caused by multiple abscesses in the intraperitoneal, hepatic,
and pulmonary areas [103, 104].
To avoid these infectious complications, we have pro-
posed performing a microsurgical technique which consists
of the resection of the extrahepatic biliary tract [102, 103,
105]. The use of broad-spectrum antibiotics and vitamin
K allows the long-term evolution of the rats [102, 103].
In the long-term evolution (8 to 10 weeks), microsurgical
extrahepatic cholestatic rats develop hepatomegaly with a
marked ductular proliferation and ﬁbrosis [106]( Figure 4).
It has been suggested that liver ﬁbrogenesis resembles a
wound-healing process leading to scar formation [107, 108].
The persistence of this inﬂammatory response through a
longer evolution induces an “atypical” ductular proliferation
with the development of a neuroendocrine compartmentInternational Journal of Inﬂammation 9
Table 4: Characteristics of the experimental cholestatic portal
hypertensive syndrome.
(i) Severe hemodynamic dysfunction
(ii) Increased sodium and water retention
(iii) Interstitial dysfunction
(iv) Increased mesenteric lymph ﬂow
(v) Bacterial translocation
(vi) Mesenteric adenitis
(vii) Endotoxemia
(viii) Negative acute phase response
(ix) Hypermetabolism
(x) Multiple organ dysfunction/failure
(a) Lung
( b )C e n t r a ln e r v o u ss y s t e m
(c) Kidney
(xi) Catabolism
(xii) Ascites
(xiii) Bacterial peritonitis
(xiv) Abdominal Compartment Syndrome
(xv) Sepsis
(xvi) Shock
[109]( Figure 5). In relation to extrahepatic alterations,
jaundice, choluria, PH with an enlarged spleen and collat-
eral portosystemic circulation, hepatic encephalopathy, and
ascites stand out [103, 110, 111]. Therefore, experimental
extrahepaticcholestasisisagoodmodelnotonlyforstudying
chronichepaticdiseaserelatedtobiliaryobstruction,butalso
for studying extrahepatic complications, particularly ascites.
In the rat, chronic liver disease secondary to obstructive
cholestasis produces progressive hemodynamic dysfunction
with ascites and hepatorenal syndrome. Bile duct-ligated
rats after four weeks of biliary obstruction present an
initial disturbance in renal function associated with ascites.
Two weeks later, rats with obstructive cholestasis clearly
developed hepatorenal syndrome with ascites [112]. In these
chronic phases of macrosurgical obstructive cholestasis,
high rates of bacterial translocation, with endotoxemia
and consecutive systemic inﬂammatory response, also exist
[113]( Table 4). In rats with obstructive cholestasis, the
portal hypertensive syndrome with low-degree splanchnic
and systemic inﬂammation can progress to severe systemic
inﬂammatory response syndrome leading to multiple organ
failure. After extrahepatic cholestasis, the rat can suﬀer the
eﬀects of generalized ischemia/reperfusion and exacerbation
of oxidative and nitrosative stress [108]. It is accepted
that there is a strong correlation between experimental
obstructive jaundice and oxidative stress [114]. BDL mainly
impairs the rat liver’s ability of antioxidant regeneration,
especially at the mitochondria level [115].
Thus, it has been demonstrated that treatment with
antioxidants improves the hepatic cellular redox status
[116, 117]. A decreased antioxidant capacity of the liver
plays an important role not only in the pathogenesis of
liver ﬁbrosis or cirrhosis but also in the evolution of the
Figure 5: Liver ﬁbrosis and biliary ductular proliferation after 6
weeks of microsurgical extrahepatic cholestasis in the rat (Masson,
100x).
portal hypertensive syndrome. In this hypothetical situation,
during the evolution of the extrahepatic cholestatic rat, the
progressive reduction of the hepatic antioxidant capacity is
added to the initial PH with low-degree oxidative stress,
which consequently represents a low-grade inﬂammatory
state. Then, the intensity of the inﬂammatory response
increases and adds severity to this syndrome [1, 2].
Long-term (6 weeks) microsurgical cholestatic rats show
a splanchnic redistribution of cytokines, with an increase
of Th1 (TNF-α and IL-1β) and Th2 (IL-4 and IL-10)
cytokine production in the small bowel and in the mesen-
teric lymph nodes [118]. It has been proposed that this
splanchnic inﬂammatory response associated with ascites
couldbemediated,amongothersfactors,bymastcells[111].
Oxidativeandnitrosativestresscouldbeanimportanttrigger
of the splanchnic mast cell activation, which could be the
cause of swelling, increased lymphatic ﬂow, and production
of peritoneal exudate [2]. In diﬀerent conditions related
to intestinal ischemia and oxidative stress, the mesenteric
lymphatic circulation is more active than portal circulation
for transporting inﬂammatory mediators released in the
intestinal wall, endotoxins, and bacteria [119, 120]. This
fact suggests that in other conditions that also produce
these alterations, like severe portal hypertensive syndrome,
the mesenteric lymph is a regional proinﬂammatory and
antiinﬂammatory mediator vehicle, that is, a splanchnic one,
but with a systemic origin [103].
The key pathophysiological role of the mesenteric lymph
has been the reason for the development of adequate10 International Journal of Inﬂammation
techniques to cannulate the rat mesenteric lymph duct [121–
123].
The relative distribution proﬁles of protein functional
classes in normal rodent mesenteric lymph diﬀer signiﬁ-
cantly from that reported for plasma. The most abundant
protein classes in mesenteric lymph are protease inhibitors,
immune-related proteins, particularly those implicated in
innate immunity, and carrier proteins [124]. Therefore,
mesenteric lymph has a unique proﬁle compared with
plasma and thus represents more than a simple ﬁltrate
[124]. Recent proteomic analyses of posthemorrhagic shock
mesenteric lymph have documented the increase of proteins
functionally implicated in tissue inﬂammation [125]. These
results provide a starting point for investigating in depth
the pathophysiological role of mesenteric lymph in other
conditions in which it is considered that the gastrointestinal
tract is the engine of multiple organ dysfunction, like the
portalhypertensivesyndrome.Mesentericlymphﬂowisgen-
erally believed to increase during intestinal inﬂammation.
Although it is known that the mesenteric lymphatic system is
intimatelyinvolvedinandhighlyalteredduringtheintestinal
inﬂammation, the exact role of lymphatics is not yet known
[126]. The mesenteric lymphatic system plays essential roles
for transporting ﬂuid, proteins, lipids, and immune cells. All
these vital functions rely on the contractile and relaxation
activities of the lymphatic vessel wall [127, 128]. Therefore,
the release of inﬂammatory mediators in the intestinal
interstitial space could play a pivotal role in modulating
lymphatic vessel contractile activity. To this respect, mast cell
intestinal hyperplasia in decompensated portal hypertensive
rats could play a pivotal role in tissue swelling mediated
by lymphatic contractile dysfunction. Increased interstitial
pressure with lymphatic dysfunction in portal hypertensive
gastroenteropathy could be also involved in the leakage of
protein-rich lymph, causing a protein-losing enteropathy.
T h es e r u mp r o t e i nl e v e l sm o s ta ﬀected by this process are
those with limited ability to rapidly respond to such losses
and generally have longer half-lives such as albumin [129].
If so, the hypoalbuminemia related with the cholestatic liver
d i s e a s ew o u l db ea g g r a v a t e d[ 103] which, in turn, would
favor the production of interstitial edema.
Using the transcription factor Prox 1, expressed in
lymphatic endothelial cells, as a marker of lymphangio-
genesis [130, 131], we have shown that in the intestinal
mucosa/submucosa of rats with microsurgical cholestasis,
a lymphatic hyperplasia is produced (unpublished results)
(Figure 6). The associated expression of vascular endothelial
growthfactor(VEGF)inthesmallbowelinthisexperimental
model suggests that this lymphatic growth factor could be
an etiopathogenic factor of portal enteropathy, both due to
the production angiogenesis and lymphangiogenesis [131]
(Figure 7).
Given that the splenic vein ﬂows into the portal vein, any
increase in portal pressure leads to an increase in the splenic
venouspressure.Thisincreaseinthesplenicvenouspressure,
in turn, increases intrasplenic ﬂuid extravasation. As the
splanchnic congestion worsens, intrasplenic microvascular
pressure remains elevated and ﬂuid eﬄux may overload
the splenic lymphatic system, leading to an accumulation
(a)
(b)
Figure 6: Intestinal lymphangiogenesis (a, b) is increased in rats
with microsurgical extrahepatic cholestasis.  indicates lymphatic
vessels lumen, and arrows indicate stained lymphatic endothelium.
Immunohistochemical staining with Prox-1 antibody (×40).
of excess ﬂuid in the perivascular third spaces [132, 133].
Also in PH, a splenorenal and hepatorenal reﬂex-mediated
reduction in renal vascular conductance has been described,
which exacerbates sodium and water retention in the kidney
and may eventually contribute to renal dysfunction [133].
Functional renal abnormalities that occur as a consequence
of decreased eﬀective arterial blood volume are responsible
for ﬂuid accumulation in the form of ascites and hepatic
hydrothorax [45]. Ascites is the most common complication
of PH and poses an increased risk for infections and renal
failure [40, 45].
Contrary to prior belief, mesothelial cells that line the
surfaces of the peritoneal cavity are not passive cells in
ascites [134]. However, their ability to synthesize numerous
cytokines, matrix proteins, intercellular adhesion molecules,
and growth factors and their ability to present antigens to
lymphocytes could play a critical role as immunomodulators
during peritoneal injury and inﬂammation [134, 135]. The
mesothelial response to PH associated with chronic liver
diseases could be characterized by an acute-on-chronic
inﬂammation that induces an increased vascular permeabil-
ity, activation and expansion of the peritoneal macrophageInternational Journal of Inﬂammation 11
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Figure 7: Increased intestinal levels of Vascular Endothelial Growth
Factor (VEGF)-A in sham-operated (SO) and microsurgical micro-
surgical obstructive cholestatic rats (MC). The VEGF-A expression
was assayed by Western blot and quantiﬁed by optical densitometry
(O.D). ∗∗∗P<. 001: statistically signiﬁcant value in relation with
SO.
and mast cell population, release of pro- and antiinﬂam-
matory mediators, increased matrix metalloproteinases, and
tissue remodeling through subperitoneal angiogenesis and
lymphangiogenesis. Peritoneal oxidative stress induced by
chronic liver disease could induce acute mesothelial expres-
sion of proinﬂammatory, proangiogenic and proﬁbrotic
mediators as has been described in other peritoneal injury
types[136].Particularly,ratperitonealmastcells(connective
tissue mast cells) could play a main role in this hypothetical
inﬂammatory process [137].
At last, ascites increases abdominal pressure, a contin-
uum of pathophysiologic changes beginning with regional
blood ﬂow disturbance and culminating in frank end-
organ failure and the development of Abdominal Compart-
ment Syndrome [138]. Elevated intra-abdominal pressure
compresses thin walled mesenteric veins promoting venous
hypertension, intestinal interstitial edema, bacterial translo-
cation, sepsis, and multiple organ failure [138, 139].
Bacterial translocation provides a mechanism for the
pathogenesisofbacterialinfectionsinexperimentalcholesta-
sis [140]. Increased production of TNF-α m a yp l a ya n
importantroleintheprocessofbacterialtranslocationinrats
with cirrhosis and ascites because TNF-α blockade is able to
downregulate it without increasing the incidence of systemic
infections [141]. Jaundice is also an important mediator
of the splanchnic and systemic inﬂammatory response in
experimental models of cholestasis [108]. Bilirubin has a
number of new and interesting biochemical and biological
properties. In addition to having a protective role against
oxidative stress, bilirubin has antiapoptotic and antimuta-
genic properties, as well as a strong role as an immune mod-
ulator [142]. Cholestatic jaundice also occurs in the setting
of sepsis. Liver abnormalities in sepsis include cholestasis
and hyperbilirubinemia. Hyperbilirubinemia particularly
develops in sepsis in the setting of bacteriemia and precedes
positive blood cultures in a third of all cases [143].
Besides ascites, serious complications such as SBP fre-
quently ensue in decompensated cirrhosis [144]. SBP devel-
opsfromthetranslocationofbacteriafromtheintestine,and
successful management with early diagnosis and treatment
with proper prevention in patients of high risk are necessary
[144, 145]. Culture-negative neutrocytic ascites is considered
to be a variant of SBP. The diagnosis of this variant is
made when a patient has an elevated ascites ﬂuid absolute
polymorphonuclear leukocyte count, with a negative ascites
ﬂuid culture and no evident intra-abdominal surgically
treatable source of infection [146]. Patients with ascitic ﬂuid
infectionarepronetodevelopsepsis,severesepsis,andseptic
shock [146, 147]. Interestingly enough, after surviving the
ﬁrst episode of ascitic ﬂuid infection, hepatic failure and
hypovolemic shock comprised a signiﬁcant proportion of
mortality, in addition to septic shock [146].
Ascites is the pathologic accumulation of ﬂuid in the
peritoneal cavity and is a common manifestation of liver
failure, being one of the cardinal signs of PH [148].
Ascitic ﬂuid formation is a not well-known pathogenic
mechanism. However, ascitic ﬂuid is a bioactive medium
containing electrolytes, with high levels of sodium, proteins
including albumin and enzymes, as well as cells including
leukocytes [146]. Some of these characteristics make it
similar to another bioactive medium, the amniotic ﬂuid
[149–151]. Amniotic ﬂuid, the protecting liquid contained
in the amnion cavity, is an essential component for fetal
development and maturation during pregnancy [150, 152].
Body ﬂuid is distributed among three major ﬂuid spaces:
intracellularﬂuid,interstitialﬂuid,andplasma.Nevertheless,
the distribution of ﬂuid in each of these compartments is
dramatically diﬀerent in the fetus compared to the adult
[153]. Particularly, the amniotic ﬂuid that surrounds the
fetus may be considered an extension of the extracellular
space of the fetus [152, 153]. Thus, the lymphatic system
plays an essential role in the regulation of ﬂuid distribution
between the plasma and the interstitial ﬂuid and probably
with the amniotic ﬂuid [153]. In patients with PH and
ascites, it could also be hypothesized that the lymphatic
splanchnic system plays a key role in the ﬂuid distribution
between the plasma and the ascitic ﬂuid. If so, a pathological
pathway of increasingly complex structures with a similar
function to the management of the extracellular ﬂuid would
be formed.
At the early stages of pregnancy, amniotic ﬂuid consists
of a ﬁltrate of maternal blood [151, 154]. That is why
drugs taken by the mother can enter amniotic ﬂuid by12 International Journal of Inﬂammation
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Figure 8: Comparative and schematic view of the amniotic egg
and ascites in the decompensated portal hypertensive syndrome.
Amniotic ﬂuid circulates through the gastrointestinal tract of the
embryo favoring its trophism and maturation. On the contrary, in
the adult organism the proposed equivalent ﬂuid, the ascitic ﬂuid,
is conﬁned within peritoneal cavity. E: embryo; YS: yolk sac; I:
intestine; L: liver.
diﬀusion across the placenta during this period [151, 155].
However, its composition is known to change as pregnancy
proceeds [149]. At these stages, amniotic ﬂuid is a bioactive
medium actively secreted by the cells lining the amniotic
cavity, and as gestation progresses it includes signiﬁcant
volume of fetal urine [156]. The hypothetical comparison
of the characteristics of amniotic and ascitic ﬂuids would
oblige raising again the role of peritoneal mesothelial cells
in the etiopathogeny of ascites that occurs in the portal
hypertensive syndrome (Figure 8). The ﬁrst ﬂuid to enter the
gastrointestinal system is amniotic ﬂuid, and it contributes
to fetal nutritional requirements and plays a signiﬁcant role
in gut development and maturation [156]. Thus, growth-
promoting eﬀects of amniotic ﬂuid are equivalent to human
milk [156]. The trophic eﬀect of orally consumed amniotic
ﬂuid is attributed in part to its content in growth factors,
includingepidermalgrowthfactor(EGF),hepatocytegrowth
factor (HGF), transforming growth factor-alpha (TGF-α),
ﬁbroblast growth factor (FGF), insulin-like growth factor
(IGF-s), and VEGF [156, 157].
The functional comparison of amniotic and ascitic ﬂuids
would imply that in the decompensated portal hypertensive
syndrometheabdominalmesotheliumacquirespropertiesof
the amniotic membranes or amnion. This hypothesis would
imply several suppositions or suggestions. For example, the
intestine in the case of portal hypertensive ascites could not
beneﬁt from the supposed trophic properties of the ascites
ﬂuid, given that the peritoneal cavity-gastrointestinal tract
pathway doesn’t exist. Likewise, the prenatal interruption
of the amniotic ﬂuid transit in cases of prenatal intesti-
nal obstruction prevents the fetus from beneﬁting from
its trophic properties, and it has been suggested that it
contributes to fetal undergrowth [158].
The amniotic membrane is a tissue of particular interest
because it possesses cells characteristic of stem cells with
multipotent diﬀerentiation ability [159, 160]. Therefore,
exploring the possibilities that the “ascitic peritoneum”
would oﬀer as a source of stem cells and growth factors could
open new paths of knowledge for the study of its pathogeny.
Even so, the ascitic ﬂuid could be a source of powerful
therapies for using its supposedly beneﬁcial properties. The
embryonic regression of the peritoneum that induces the
inﬂammatory response induced by PH also could favor the
presence of active antimicrobial components as has been
described in the amniotic ﬂuid [161]. Thus, the resistance
to infection of the ascites would be explained, with usual
subtle clinical manifestations in cases of secondary bacterial
peritonitis [144, 145].
We have previously proposed the hypothesis that inﬂam-
mationwouldrepresentthedebutduringthepostnatallifeof
ancestralbiochemicalmechanismsthatwereusedfornormal
embryonic development [1, 18]. The re-expression of these
old mechanisms, with a prenatal solvent path, is perhaps
inappropriate; they are anachronistic during postnatal life
since they are established in a diﬀerent environmental
medium [162, 163]. That is why in the current paper, we
propose the hypothetical existence of a regression to the pre-
natal functional mechanisms of the abdominal interstitium-
lymphatic-mesothelium axis, in an attempt to integrate the
existing knowledge of the portal hypertensive syndrome. In
this hypothesis, it is considered that the main objective of
this derepression of “dormant” biochemical mechanisms is
the recuperation of the amnion. The major phylogenetic
importancethatthisstructurehasperhapsliesinthefactthat
during development it protectively surrounds the embryo
and creates a ﬂuid-ﬁlled cavity in which the embryo develops
[152]. Its acquisition, that is, the “amniotic egg” was one
of the main causes that enabled amniotes to escape the
bonds that conﬁned their ancestors to aquatic environments
[164, 165].
A poetic license could have been taken if we consider
that the way to escape the sea is to take the sea with you,
like an amniotic-mesothelial structure full of saline ﬂuid.
Since this ability would be associated in the postnatal life
to mesothelial cells, its major spread through the body is
not surprising; coating cavities (aracnoides, sinovial, pleura,
testicular vaginal) to create virtual spaces that face trauma,
infectionoratumorquicklycarryoutanexudativeresponse.
Therefore, although the mesothelial exudative inﬂammatory
response is considered pathological, its proven evolutive and
beneﬁcial characteristics should not be forgotten from the
embryonic, ontogenic, and phylogenetic points of view.
5. Conclusion
Ascites and hepatorenal syndrome are the major challenging
complications of cirrhosis and portal hypertension that
signiﬁcantly aﬀect the course of the disease. Particularly, the
development of ascites severely impairs the quality of life
and decreases the chance of survival. Obstructive cholestasis,
which causes chronic hepatic insuﬃciency and PH with
ascites,isaveryusefulexperimentalmodelforstudyingthese
complications. Several surgical techniques for developing
obstructive cholestasis have been described, especially in
the rat. The development of microsurgical techniques has
made it easier to establish a new model of obstructiveInternational Journal of Inﬂammation 13
cholestasisintheratthatpreventsthecomplicationsinherent
to macrosurgical techniques based on BDL.
The liver has been assumed to be the likely source of
ascites in patients with liver disease, but the cirrhotic liver
is not the sole or even the major source of ascites in most
patients. Weeping of ﬂuid in excess from the peritoneal
lining and serosal surfaces of the bowel is often striking in
PH as are dilated lymphatics on the surface of the small
intestine, in the mesentery and within the retroperitoneal
space. Therefore, it is accepted that when lymphatic drainage
mechanisms are overwhelmed, excess lymph is collected in
the peritoneal cavity, thus causing ascites. The mesothelial
response to PH associated with chronic liver disease, could
be characterized by an acute-on-chronic inﬂammation.
In patients with PH and ascites, it could be hypothesized
that the lymphatic splanchnic system in continuity with
peritoneal mesothelial cells plays a key role in abnormal
body ﬂuid distribution resulting in ascites. The hypothetical
comparison of the characteristics of amniotic and ascitic
ﬂuids would oblige raising again the role of peritoneal
mesothelial cells in the etiopathogeny of ascites that occurs
in the portal hypertensive syndrome. The functional
comparison of amniotic and ascitic ﬂuids could imply that
in the decompensated portal hypertensive syndrome the
abdominal mesothelium expresses properties similar to
those of the amniotic membranes.
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